Actively Recruiting
Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes
Led by Wecare Probiotics Co., Ltd. · Updated on 2025-03-30
80
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.
CONDITIONS
Official Title
Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women diagnosed with gestational diabetes mellitus at 24 weeks of gestation based on abnormal oral glucose tolerance test
- Pregnant women aged 18 to 50 years
- Singleton pregnancy with fetus confirmed structurally and chromosomally normal by ultrasound or prenatal diagnosis
- No history of chronic diseases including immune deficiency, hypertension, diabetes, kidney disease, or liver disease
- No consumption of probiotic-containing foods in the two weeks prior to the study
- Willing and able to provide written informed consent
- Able to comply with study protocol and follow-up requirements
You will not qualify if you...
- Use of similar functional products to the test product in the short term affecting results
- Presence of other endocrine diseases or use of medications affecting blood glucose control
- Severe cardiovascular, kidney, or liver diseases
- Immunodeficiency diseases or use of immunosuppressive agents
- Severe gastrointestinal diseases affecting probiotic absorption or metabolism
- Use of medications that affect blood glucose or lipid levels
- History of allergy to probiotics or any study product components
- Unhealthy lifestyle habits such as smoking, alcohol use, or drug abuse
- Failure to consume test samples as required or failure to follow up on time
- Participants deemed unsuitable by other researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Actively Recruiting
Research Team
X
Xiao Wu, Doctor
CONTACT
X
Xiao Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here